Trial reportBMC gastroenterology2026
Vonoprazan-amoxicillin dual therapy combined with probiotics for Helicobacter pylori eradication: a prospective, multicenter, randomized controlled trial.
Trial report in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe probiotic may help restore treatment-impaired gut microbiota and promote beneficial bacterial colonization, but its specific impact on Helicobacter pylori (H. pylori) eradication efficacy and safety remains unclear. This study aimed to evaluate the role of Bacillus subtilis dual viable bacteria capsules (Medilac-S) as an adjunct to dual therapy, focusing on its impact on treatment safety and H. pylori eradication efficacy.
methodsFrom April 1 to August 1, 2024, 220 H. pylori-positive patients were enrolled. They were randomly assigned to two treatment groups: the Probiotics Group (receiving Medilac-S, two capsules three times daily; vonoprazan 20 mg twice daily; amoxicillin 1000 mg three times daily) and the Dual Therapy Group (vonoprazan 20 mg twice daily; amoxicillin 1000 mg three times daily). Both groups underwent a 14-day treatment course. At least four weeks after treatment completion, a 13C-urea breath test was performed. H. pylori eradication rates, adverse event incidence, and medication compliance were compared between the two groups.
resultsEradication rates did not differ significantly between groups in intention-to-treat (91.8% vs. 90.9%, P = 0.810), modified intention-to-treat (96.2% vs. 94.3%, P = 0.527), or per-protocol analyses (96.1% vs. 95.1%, P = 0.722). However, the Probiotics Group had significantly fewer adverse events (11.4% vs. 23.6%, P = 0.020). Medication compliance showed no significant difference between the groups (P = 0.414). The occurrence of adverse events was identified as a risk factor for eradication failure (OR = 12.000, P = 0.001).
conclusionAdding Medilac-S as an adjunct to vonoprazan-amoxicillin dual therapy resulted in satisfactory H. pylori eradication. Although the difference in eradication rates between the Probiotics Group and the Dual Therapy Group was not statistically significant, the Probiotics Group showed numerically higher, but not statistically significant, success rates across PP, mITT, and ITT analyses, along with a significant reduction in treatment-related adverse events. Patients experiencing adverse events were more likely to have eradication failure.
trial registrationhttps://www.medicalresearch.org.cn/ , identifier ChiCTR2400082446. Registered on March 29, 2024.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.